Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-Tazobactam Dosing Optimization in Elderly Pneumonia
NCT06972537Recruiting
- Sponsor
- Shandong University
- Start
- Jul 2024
- Primary completion
- Sep 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of piperacillin + tazobactam in pneumonia (2 arms), sponsored by Shandong University. Primary endpoint: Clinical improvement rate at 3 months. Started Jul 2024; status: recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT06972537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972537.